This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
| less than a minute read

Extending patent protection for life science companies

How far does the new doctrine of equivalents introduced by the UK Supreme Court in Eli Lilly v Actavis really extend the scope of patent protection for pharma companies in the UK?  (My own thoughts here).  Last night I attended a highly anticipated discussion of the case involving Lord Neuberger, who gave the leading judgment in the case. The important take away was that pharma companies do now have greater protection against those trying to circumvent their patents using a variant that was overlooked in the patent's claims.  And that, whilst one can never achieve complete harmony accross Europe, courts should now be more consistent in their decisions.  That is indeed great news for innovators!  

On 1st November 2017, UCL Faculty of Laws Institute of Brand and Innovation Law will bring together an unrivalled panel of European judges to discuss the Actavis UK Ltd v. Eli Lilly & Co [2017] UKSC 48 judgment from a range of perspectives.

Tags

patents, intellectual property, pharmaceuticals, life sciences, supreme court, litigation, doctrine of equivalents

Tweets on this subject

Related Insights